Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Therapy
New acute myeloid leukemia therapy study findings have been reported by scientists at Ludwig-Maximilians University, Department of Internal Medicine III
April 10th, 2007
Current study results from the report, "Cytotoxic activity of the third-generation bisphosphonate zoledronic acid in acute myeloid leukemia," have been published. According to recent research from Munich, Germany, "The third-generation bisphosphonate zoledronic acid (ZOL) has recently been shown to be active against human tumor and leukemic cell lines. The purpose of this study was to evaluate the antileukemic potential of ZOL in acute myeloid leukemia (AML)." "We determined the lethal concentration 50% (LC 50) using the WST-1 assay of ZOL as being 287.9 microg/ml after 24 h and 108.3 microg/ml after 96 h in HL 60 cells and to be 382.4 and 43.2 microg/ml, respectively,...
Source: Drug Law Weekly (2007-04-10)
|
